Validation of DNA methylation biomarkers for diagnosis of acute lymphoblastic leukemia

Clinical Chemistry

Volumn 60, Issue 7, 2014, Pages 995-1003

  Chatterton, Zac ^a,f   Burke, Daniel ^b   Emslie, Kerry R ^b   Craig, Jeffery M ^c   Ng, Jane ^a   Ashley, David M ^d   Mechinaud, Francoise ^e   Saffery, Richard ^a   Wong, Nicholas C ^a,g  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c NATIONAL MEASUREMENT INSTITUTE   (Australia)

^d DEAKIN UNIVERSITY   (Australia)

^e ROYAL CHILDREN'S HOSPITAL   (Australia)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g AUSTIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FORKHEAD BOX E3 PROTEIN; SYNTHETIC DNA; T CELL LEUKEMIA HOMEOBOX; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CHILDHOOD LEUKEMIA; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLEARANCE; DNA METHYLATION; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; LEUKEMIA RELAPSE; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MINIMAL RESIDUAL DISEASE; PROMOTER REGION; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DNA METHYLATION; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE DOSAGE; GENETIC MARKERS; HOMEODOMAIN PROTEINS; HUMANS; INFANT; LIMIT OF DETECTION; MALE; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROMOTER REGIONS, GENETIC; REFERENCE STANDARDS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84903705690     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2013.219956     Document Type: Article

References (36)

1. Baylin SB, Jones PA. A decade of exploring the cancer epigenome: biological and translational implications. Nat Rev Cancer 2011;11:726-34.
2. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
3. Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun HM, Van Den Berg D, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 2012;22:271-82.
4. Deneberg S, Guardiola P, Lennartsson A, Qu Y, Gaidzik V, Blanchet O, et al. Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks. Blood 2011;118:5573-82.
5. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4.
6. Esteller M, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, Watkins DN, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 2000;60:2368-71.
7. Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB, Herman JG. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res 1998;58:4515-8.
8. Wong NC, Ashley D, Chatterton Z, Parkinson-Bates M, Ng HK, Halemba MS, et al. A distinct DNA methylation signature defines pediatric pre-B cell acute lymphoblastic leukemia. Epigenetics 2012;7:535-41.
9. Clark SJ, Statham A, Stirzaker C, Molloy PL, Frommer M. DNA methylation: bisulphite modification and analysis. Nat Protoc 2006;1:2353-64.
10. Begemann M, Leisten I, Soellner L, Zerres K, Eggermann T, Spengler S. Use of multilocus methylation-specific single nucleotide primer extension (Ms-SNuPE) technology in diagnostic testing for human imprinted loci. Epigenetics 2012;7:473-81.
11. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, et al. Methylight: a highthroughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
12. Gordon L, Joo JE, Powell JE, Ollikainen M, Novakovic B, Li X, et al. Neonatal DNA methylation profile in human twins is specified by a complex interplay between intrauterine environmental and genetic factors, subject to tissue-specific influence. Genome Res 2012;22:1395-406.
13. Novakovic B, Yuen RK, Gordon L, Penaherrera MS, Sharkey A, Moffett A, et al. Evidence for widespread changes in promoter methylation profile in human placenta in response to increasing gestational age and environmental/stochastic factors. BMC Genomics 2011;12:529.
14. Clark S, Harrison C, Paul C, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994;22:2990-7.
15. Thompson RF, Suzuki M, Lau KW, Greally JM. A pipeline for the quantitative analysis of CG dinucleotide methylation using mass spectrometry. Bioinformatics 2009;25:2164-70.
16. Thomsen V, Schatzlein D, Mercuro D. Limits of detection in spectroscopy. Spectroscopy 2003;18:112-4.
17. Ding C, Chiu RW, Lau TK, Leung TN, Chan LC, Chan AY, et al. MS analysis of single-nucleotide differences in circulating nucleic acids: application to noninvasive prenatal diagnosis. Proc Natl Acad Sci USA 2004;101:10762-7.
18. Ehrich M, Turner J, Gibbs P, Lipton L, Giovanneti M, Cantor C, van den Boom D. Cytosine methylation profiling of cancer cell lines. Proc Natl Acad Sci USA 2008;105:4844-9.
19. Chatterton Z, Morenos L, Mechinaud F, Ashley DM, Craig JM, Sexton-Oates A, et al. Epigenetic deregulation in pediatric acute lymphoblastic leukemia. Epigenetics 2014;9:459-67.
20. Coolen MW, Statham AL, Gardiner-Garden M, Clark SJ. Genomic profiling of CpG methylation and allelic specificity using quantitative highthroughput mass spectrometry: critical evaluation and improvements. Nucleic Acids Res 2007;35:e119.
21. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011;29:551-65.
22. van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998;352:1731-8.
23. Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med 1998;339:591-8.
24. Goulden NJ, Knechtli CJ, Garland RJ, Langlands K, Hancock JP, Potter MN, et al. Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia. Br J Haematol 1998;100:235-44.
25. Campana D. Progress of minimal residual disease studies in childhood acute leukemia. Curr Hematol Malig Rep 2010;5:169-76.
26. Coustan-Smith E, Sancho J, Behm FG, Hancock ML, Razzouk BI, Ribeiro RC, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002;100:52-8.
27. Nyvold C, Madsen HO, Ryder LP, Seyfarth J, Svejgaard A, Clausen N, et al. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood 2002;99:1253-8.
28. Bailey LC, Lange BJ, Rheingold SR, Bunin NJ. Bone-marrow relapse in paediatric acute lymphoblastic leukaemia. Lancet Oncol 2008;9:873-83.
29. Rubnitz JE, Campbell P, Zhou Y, Sandlund JT, Jeha S, Ribeiro RC, et al. Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia. Cancer 2013;119:2061-6.
30. Lee BB, Lee EJ, Jung EH, Chun HK, Chang DK, Song SY, et al. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res 2009;15:6185-91.
31. Adams D, Altucci L, Antonarakis SE, Ballesteros J, Beck S, Bird A, et al. Blueprint to decode the epigenetic signature written in blood. Nat Biotechnol 2012;30:224-6.
32. Bernstein BE, Stamatoyannopoulos JA, Costello JF, Ren B, Milosavljevic A, Meissner A, et al. The NIH roadmap epigenomics mapping consortium. Nat Biotechnol 2010;28:1045-8.
33. Novak P, Stampfer MR, Munoz-Rodriguez JL, Garbe JC, Ehrich M, Futscher BW, Jensen TJ. Celltype specific DNA methylation patterns define human breast cellular identity. PloS One 2012;7:e52299.
34. Sehouli J, Loddenkemper C, Cornu T, Schwachula T, Hoffmuller U, Grutzkau A, et al. Epigenetic quantification of tumor-infiltrating T-lymphocytes. Epigenetics 2011;6:236-46.
35. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
36. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010;28:1145-53.